Found 1286 clinical trials
PTX-35 in Patients With Advanced Solid Tumors
A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care
- 0 views
- 19 Feb, 2024
RTX-240 Monotherapy
Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors.
- 0 views
- 19 Feb, 2024
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
This is a Phase 1, multicenter, open-label, multiple-dose, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, and pharmacodynamics of TTX-080 monotherapy in subjects with advanced or metastatic solid tumors known to express HLA-G. This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and preliminary antitumor …
- 0 views
- 19 Feb, 2024
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer …
- 0 views
- 19 Feb, 2024
First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors
ABBV-CLS-579 is an investigational drug being developed for the treatment of solid tumors. The study has two arms - Monotherapy and Combination Therapy. In the monotherapy arm, participants will receive ABBV-CLS-579 alone, in increasing doses.
- 0 views
- 19 Feb, 2024
A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors
A first-in-human (FIH) study using SBT6050 in HER2 expressing advanced malignancies
- 0 views
- 19 Feb, 2024
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors
This study is a multi-center, open-label, dose escalation study of RLY-1971 in subjects with advanced or metastatic solid tumors.
- 0 views
- 19 Feb, 2024
A Trial of ZL-1201 in Subjects With Advanced Cancer
First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer
- 0 views
- 19 Feb, 2024
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors. Additionally, the trial will monitor anti-tumor effects on both injected lesions and distant non-injected deposits.
- 0 views
- 19 Feb, 2024
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response.
- 0 views
- 19 Feb, 2024